EUVIMEDEUVIMED entdecken
Crossref

Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac

V O Omelchenko, Yu D Kurochkina, A V Fedorova, V S Ovchinnikov, V V Koval, I V Bratko, E A Letyagina, M A Korolev

Bulletin of Experimental Biology and Medicine · 2024

DOI: 10.1007/s10517-024-06109-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bulletin of Experimental Biology and Medicine, 2024. Verfasst von V O Omelchenko und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology - Branch of the Federal Research Center Institu…. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Rituximab, Immunity, Humoral, SARS-CoV-2. Die Arbeit nennt 11 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic has brought significant changes in managing of patients with rheumatoid arthritis. Rituximab-treated patients were more susceptible to severe infection. This required a "switch" to another genetically engineered drug in the patients with high risk of adverse COVID-19. In this study, we assessed the severity of immune response to SARS-CoV-2 antigens in rituximab-treated patients with rheumatoid arthritis vaccinated with the combined vector vaccine Gam-COVID-Vac. Insufficient formation of the humoral response and a high level of T-cell response to SARS-CoV-2 antigens in this group of patients were revealed. An imbalance of cellular and humoral response may play a role in more severe COVID-19 in rituximab-treated patients with rheumatoid arthritis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Arthritis, RheumatoidRituximabImmunity, HumoralSARS-CoV-2COVID-19COVID-19 VaccinesHumansMiddle AgedMaleFemaleT-LymphocytesAgedAntibodies, ViralAdultAntirheumatic AgentsVaccination

Stichwörter der Autor:innen

SARS-CoV-2rheumatoid arthritisrituximabvaccination

Substanzen

RituximabCOVID-19 VaccinesAntibodies, ViralAntirheumatic Agents

Autor:innen und Institutionen

  • Laboratory of Connective Tissue Pathology, Research Institute of Clinical and Experimental Lymphology - Branch of the Federal Research Center Institute of Cytology and Genetics, Siberian Branch of the Russian Academy of…

Zitieren

APA

Omelchenko, V. O., Kurochkina, Y. D., Fedorova, A. V., Ovchinnikov, V. S., Koval, V. V., Bratko, I. V., Letyagina, E. A., & Korolev, M. A. (2024). Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac. Bulletin of Experimental Biology and Medicine. https://doi.org/10.1007/s10517-024-06109-9

Vancouver

Omelchenko VO, Kurochkina YD, Fedorova AV, Ovchinnikov VS, Koval VV, Bratko IV, et al. Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac. Bulletin of Experimental Biology and Medicine. 2024. doi:10.1007/s10517-024-06109-9

BibTeX
@article{Omelchenko2024,
  author = {Omelchenko, V O and Kurochkina, Yu D and Fedorova, A V and Ovchinnikov, V S and Koval, V V and Bratko, I V and Letyagina, E A and Korolev, M A},
  title = {Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac},
  journal = {Bulletin of Experimental Biology and Medicine},
  year = {2024},
  doi = {10.1007/s10517-024-06109-9}
}
Kostenlos starten →